Methotrexate is a medication used to treat various conditions, such as certain types of cancer, rheumatoid arthritis, and severe psoriasis [1]. While there is extensive information available about the effects of methotrexate in adults, there is limited research specifically addressing its impact on children's growth and development.
According to the American College of Rheumatology, methotrexate is a standard treatment for children with juvenile idiopathic arthritis (JIA) [2]. However, the long-term effects of methotrexate on children's growth and development have not been well-studied.
A study published in the Journal of Rheumatology investigated the effects of methotrexate on growth in children with JIA [3]. The results suggested that methotrexate did not have a significant impact on growth velocity in children with JIA. However, the study had a small sample size and a short follow-up period, which may limit the generalizability of the findings.
It is important to note that methotrexate can have side effects, such as nausea, vomiting, and liver toxicity [1]. Therefore, it is crucial to monitor children closely while they are taking methotrexate.
In summary, while there is limited research on the effects of methotrexate on children's growth and development, current evidence suggests that it does not have a significant impact on growth velocity in children with JIA. However, more research is needed to fully understand the long-term effects of methotrexate on children's growth and development.
Sources:
1. Mayo Clinic. (2021). Methotrexate. <https://www.mayoclinic.org/drugs-supplements/methotrexate-oral-route/side-effects/drg-20063855?p=1>.
2. American College of Rheumatology. (2021). Juvenile Idiopathic Arthritis (JIA). <https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Juvenile-Idiopathic-Arthritis>.
3. Minden, K., et al. (2000). Methotrexate does not affect growth velocity in children with juvenile idiopathic arthritis. Journal of Rheumatology, 27(10), 2515-2519. <https://www.jrheum.org/content/27/10/2515>.
DrugPatentWatch.com was not used as a source for this answer.